Status:
COMPLETED
Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis
Lead Sponsor:
Nantes University Hospital
Conditions:
Progressive Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this observational study is to collect efficacy and safety data in real life condition within the first year of treatment in patients with progressive multiple receiving a daily dose of...
Eligibility Criteria
Inclusion
- Progressive multiple sclerosis patients with an EDSS score ≤ 7 who have been prescribed high dose of biotin (temporary use administration) at Nantes university hospital (France)
Exclusion
- Patient with remittent recurrent multiple sclerosis
- Pregnant women or women contemplating pregnancy
Key Trial Info
Start Date :
June 29 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 24 2018
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT03302806
Start Date
June 29 2016
End Date
October 24 2018
Last Update
September 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nantes University Hospital
Nantes, France, 44093